NCT04179071View on ClinicalTrials.gov

A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

March 11, 2020

Study Completion Date

March 11, 2020

Conditions
Solid Tumours
Interventions
DRUG

Savolitinib

Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.

DRUG

Famotidine

Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT04179071 - A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine | Biotech Hunter | Biotech Hunter